AlphAIAlphAI — Financial news for AI agents
investing.com$LQDA

BTIG raises Liquidia stock price target to $87 on strong demand

BTIG raised its price target for Liquidia Technologies (LQDA) to $87 from $70, citing strong demand for Yutrepia and increased 2027 EPS estimates. LQDA's Q3 revenue beat expectations at $225.3M, with Yutrepia sales up 31%, though GAAP EPS loss was $2.64 due to a $389.7M settlement charge. Jefferies also raised its target to $62, maintaining a Buy rating.

Original reporting
investing.com
Published Nov 10, 2026, 6:13 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Nov 10, 2026, 6:15 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
AlphAI market briefFinancial news
Primary signal
$LQDA
Bullish
high confidence
Mentioned
$LQDA
Relevance
7/10
AlphAI data visualization · based on investing.com
Decision brief

The 30-second read

$LQDABullishMed
01

Why it matters

Analyst upgrades could trigger short-covering and new buying, modestly lifting the stock.

02

Market read

The price target increase provides a fresh catalyst for LQDA, offering a modest trading opportunity.

03

What to watch

Potential regulatory scrutiny on Yutrepia and competition in pulmonary hypertension market.

Relevance 7/10Novelty 7/10Timing: today

Background

Liquidia recently reported Q3 revenue beat and a large settlement charge, prompting analyst upgrades.

Company-level read

Ticker impact

$LQDABullishHigh confidence
Context

BTIG raised its price target on Liquidia Technologies to $87 from $70, citing strong demand and settlement resolution.

Expected impact

likely upward pressure as investors price in higher valuation expectations

Evidence & confidence

Target raise reflects improved outlook on demand and earnings, which can attract buying.

Market effects

Sector

Positive outlook may lift other biotech firms with similar drug delivery platforms.

Regional

Limited to US biotech sector; no broader regional effect.

Global

Minimal global impact beyond niche biotech investors.

Counterpoint

What could challenge this read

Target raise may be premature if settlement costs recur or demand stalls.

Key entities

  • company
    Liquidia Technologies

    Biotech firm developing inhaled therapies.

  • analyst
    BTIG

    Investment bank that raised the price target.

Read at source← All news

Related articles

$LQDAMed

Jefferies raises Liquidia stock price target to $62 on revenue growth

Jefferies raised its price target on Liquidia (NASDAQ:LQDA) to $62 from $55, maintaining a Buy rating. The company reported Q3 revenue of $222.7M, up 31% sequentially, with a GAAP EPS loss of $2.64 due to a $389.7M settlement charge. Adjusted EBITDA rose to $140.5M, and the stock has returned 76% over the past year. Jefferies expects 2027 revenue to reach $910M, citing strong growth in pulmonary arterial hypertension treatments.

investing.com
$LQDAMedAI 8/10

Why is Liquidia stock gaining today?

Liquidia Corporation (LQDA) shares rose 1.4% in pre-market trading after reporting Q3 2026 results. Revenue of $225.3M beat estimates, driven by $222.7M in YUTREPIA sales, up 31% from the prior quarter. A $389.7M litigation charge resulted in a GAAP net loss of $2.64 per share, but operational metrics showed growth, including record patient shipments and an expanding prescriber base. The company's cash position increased to $396.1M.

investing.com
$LQDAMed

Liquidia Reports Strong Third-Quarter YUTREPIA Sales Growth

Liquidia (LQDA) reported Q3 2026 net sales of $222.7M for YUTREPIA, up 31% from Q2, with October patient shipments at a record high. The company settled litigation with United Therapeutics, incurring a $389.7M charge and a Q3 net loss of $236.3M. Non-GAAP adjusted EBITDA was $140.5M, up for the fifth consecutive quarter. Cash reserves were $396.1M at Q3's end. The FDA granted Fast Track designation to YUTREPIA for a new indication, and the company initiated two new studies.

tipranks.com
$LQDAHighAI 8/10

Liquidia Corporation Reports Third Quarter 2026 Financial Results

Liquidia Corp (LQDA) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Liquidia Corporation Reports Third Quarter 2026 Financial Results · YUTREPIA® (treprostinil) inhalation powder net product sales of $222.7 million in the third quarter of 2026, up 31% from the second quarter of 2026 · October 2026 total patient shipments reached thei

SEC EDGAR 8-K